Generally, RABBIT shows biologic DMARDs to be effective, safe and well tolerated in daily rheumatologic care. Used by experienced rheumatologists, they are a safe treatment option for patients with rheumatoid arthritis, who do not respond adequately to non-biologic DMARDs.

In practice, biologic DMARDs are not prescribed until non-biologic DMARDs fail or are not tolerated. That means that patients for whom biologic DMARDs are indicated differ systematically from patients who are treated with non-biologic DMARDs. Therefore, highly sophisticated statistical methods are required to compare patients on biologic and non-biologic DMARDs. Here, we will give a short insight into our published results.


Update: Mai 2nd, 2019; enrolled patients: 18,304

Amgevita┬« (Adalimumab)    18
Benepali┬« (Etanercept)  559
Cimzia┬« (Certolizumab)   874
Enbrel® (Etanercept)2857
Erelzi┬« (Etanercept)  148
Flixabi┬« (Infliximab)      1
Humira® (Adalimumab)2899
Hyrimoz┬« (Adalimumab)    16
Imraldi┬« (Adalimumab)      15
Inflectra┬« (Infliximab)    15
Kevzara┬« (Sarilumab)    61
Kineret┬« (Anakinra)    89
MabThera┬« (Rituximab) 1458
Olumiant┬« (Baricitinib)   248
Orencia┬« (Abatacept)   751
Remicade┬« (Infliximab)   762
Remsima┬« (Infliximab)    10
Rixathon┬« (Rituximab)      5
RoActemra┬« (Tocilizumab) 1300
Simponi┬« (Golimumab)   436
Xeljanz┬« (Tofacitinib)   200
Control Group 5582